A 28-year-old man from Delhi presents with a 3-month history of progressive painless cervical lymphadenopathy, fever, and night sweats. Excisional lymph node biopsy shows classical Hodgkin lymphoma (cHL), nodular sclerosis subtype. CT chest and abdomen are normal. PET-CT shows uptake only in cervical nodes (Stage IA). What is the most appropriate next step in management?
A. Observation with 3-monthly clinical review and repeat imaging
B. Combined modality therapy: 2 cycles ABVD followed by IFRT 30 Gy
C. Involved-field radiotherapy (IFRT) 30 Gy to cervical region alone
D. ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles
Explanation
Clinical Context
This patient has early-stage (Stage IA) classical Hodgkin lymphoma with favorable prognostic features (young age, limited disease, no bulky mass). The standard of care for early-stage cHL has evolved toward combined modality therapy (CMT) to optimize cure while minimizing late toxicity.
Treatment Rationale for Early-Stage cHL
Key Point
Early-stage cHL (Stage I–II) with favorable risk factors is best treated with combined modality therapy: 2–4 cycles of chemotherapy (ABVD or escalated BEACOPP) followed by involved-field radiotherapy (IFRT).
High-YieldNEET PG
The combination of chemotherapy + IFRT achieves ≥90% 5-year progression-free survival in early-stage cHL, with significantly lower relapse rates than either modality alone.
Why Combined Modality Therapy?
1.
Chemotherapy component — eradicates micrometastatic disease and systemic burden
2.
Radiotherapy component — provides local control and reduces risk of nodal relapse
3.
Reduced toxicity — 2 cycles ABVD + IFRT (30 Gy) has lower cumulative cardiopulmonary and secondary malignancy risk than either full-course chemotherapy or extended radiation alone
Dosing & Duration
ABVD: 2 cycles for early-stage favorable disease (vs. 4 cycles for intermediate/unfavorable)
IFRT: 30 Gy in 15 fractions to involved field (cervical nodes in this case)
Total duration: ~12 weeks
Clinical Pearl
Modern protocols prioritize de-escalation in favorable early-stage disease to reduce late toxicities (secondary malignancies, cardiac dysfunction, pulmonary fibrosis) while maintaining excellent cure rates.
Why Not the Other Options?
Table
Option
Why Incorrect
Observation alone
Unacceptable; early-stage cHL is curable with active treatment. Observation is not standard and risks progression.
ABVD 4 cycles only
Chemotherapy monotherapy for early-stage cHL has higher relapse rates (20–25%) compared to CMT (5–10%). IFRT is needed for optimal local control.
IFRT alone (30 Gy)
Radiotherapy monotherapy has been largely abandoned due to higher relapse rates and risk of late toxicities. Chemotherapy is essential to address systemic disease risk.
Harrison 21e Ch 104
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
